Lasmiditan for the treatment of acute attack of migraine: Systematic review and meta-analysis of randomized controlled trials
Background: Acute migraine is the most common disabling chronic neurological disorder in the world. There are a huge proportion of unmet needs in treatment efficacy and satisfaction with currently available drugs and hence need for newer agents. One such FDA-approved drug is 5-HT1F Agonist lasmidita...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Eldaghayes Publisher
2022-09-01
|
| Series: | National Journal of Physiology, Pharmacy and Pharmacology |
| Subjects: | |
| Online Access: | http://www.ejmanager.com/fulltextpdf.php?mno=141058 |
| Tags: |
No Tags, Be the first to tag this record!
|